
Cilnidipine (10mg) + Chlorthalidone (12.5mg) + Olmesartan Medoxomil (40mg)
Active composition
+2 more active ingredients
Cilnidipine inhibits L-type and N-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmin Trio 40 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40mg, Cilnidipine 10mg, and Chlorthalidone 12.5mg. Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), effectively lowers blood pressure by inhibiting the vasoconstrictive effects of angiotensin II, thereby promoting vasodilation and reducing peripheral resistance. Cilnidipine, a calcium channel blocker with dual L-type and N-type calcium channel antagonistic properties, contributes to blood pressure reduction by relaxing vascular smooth muscle and inhibiting sympathetic nerve activity. Chlorthalidone, a thiazide-like diuretic, enhances natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and reduced blood pressure. The combination of these three agents provides a complementary and synergistic mechanism to achieve optimal blood pressure control, particularly in patients with essential hypertension inadequately managed by monotherapy. Olmin Trio 40 Tablet is indicated for the treatment of hypertension to reduce the risk of cardiovascular events such as stroke and myocardial infarction. It should be used under medical supervision with regular monitoring of blood pressure, renal function, and electrolyte levels to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmin Trio 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmin Trio 40 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmin Trio 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmin Trio 40 Tablet may be needed. Please consult your doctor. Use of Olmin Trio 40 Tablet is not recommended in these patients.
Exercise Caution
Olmin Trio 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Olmin Trio 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmin Trio 40 Tablet may be needed. Please consult your doctor. Use of Olmin Trio 40 Tablet is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Olmin Trio 40 Tablet

Olmesartan Medoxomil (40mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Cilnidipine inhibits L-type and N-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmin Trio 40 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40mg, Cilnidipine 10mg, and Chlorthalidone 12.5mg. Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), effectively lowers blood pressure by inhibiting the vasoconstrictive effects of angiotensin II, thereby promoting vasodilation and reducing peripheral resistance. Cilnidipine, a calcium channel blocker with dual L-type and N-type calcium channel antagonistic properties, contributes to blood pressure reduction by relaxing vascular smooth muscle and inhibiting sympathetic nerve activity. Chlorthalidone, a thiazide-like diuretic, enhances natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and reduced blood pressure. The combination of these three agents provides a complementary and synergistic mechanism to achieve optimal blood pressure control, particularly in patients with essential hypertension inadequately managed by monotherapy. Olmin Trio 40 Tablet is indicated for the treatment of hypertension to reduce the risk of cardiovascular events such as stroke and myocardial infarction. It should be used under medical supervision with regular monitoring of blood pressure, renal function, and electrolyte levels to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmin Trio 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmin Trio 40 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmin Trio 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmin Trio 40 Tablet may be needed. Please consult your doctor. Use of Olmin Trio 40 Tablet is not recommended in these patients.
Exercise Caution
Olmin Trio 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Olmin Trio 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmin Trio 40 Tablet may be needed. Please consult your doctor. Use of Olmin Trio 40 Tablet is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Olmin Trio 40 Tablet















